Monthly Archives: May 2012

Viewpoint: the case for stricter reimbursement rules

The drug regulatory system is directed towards the approval of new medicines for particular uses, based on clinical trials and other evidence that the product is effective and safe. Yet, once approved, it is in most jurisdictions possible for a doctor to prescribe the product for whatever use s/he sees fit. This is in accordance […]

Posted in Uncategorised

Viewpoint: the case for longer drug exclusivity

I have dealt in the past with an analysis of the decline in patent-based drug exclusivity, pointing out that data exclusivity is becoming increasingly important. However, the time has come to raise the issue more broadly: the case for longer terms of commercial protection, in the interests of better medicines should be heard.

Posted in Uncategorised